Michael A. Schwarzschild, M.D., Ph.D.
This page shows the publications co-authored by Michael Schwarzschild and Grace Crotty.
If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord. 2020 10; 35(10):1727-1730.
Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology. 2020 12 15; 95(24):e3428-e3437.
Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Front Aging Neurosci. 2020; 12:186.
Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017 12; 298(Pt B):210-224.
Higher urate in LRRK2 mutation carriers resistant to Parkinson disease. Ann Neurol. 2019 04; 85(4):593-599.
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.